Y-Intercept (HK)’s Kalaris Therapeutics KLRS Stock Holding History

Y-Intercept (HK)’s Portfolio KLRS Stock Details KLRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-8,455	Closed	-$141K	–	1898
2024 Q2	$141K	Buy	+8,455	New	+$149K	0.01%	1218

Other funds holding KLRS

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Y-Intercept (HK)'s KLRS Position: Q3 2024 in Review

Y-Intercept (HK) sold out of Kalaris Therapeutics (KLRS) in Q3 2024, closing a stake of 8,455 shares — an estimated $141K sold.

Y-Intercept (HK) first reported a position in KLRS in Q2 2024 and held it in 1 quarter. The position peaked at $141K in Q2 2024. 59 funds tracked by Wall St. Rank hold KLRS as of Q3 2024.

Y-Intercept (HK) reported no remaining Kalaris Therapeutics position as of Q3 2024 after selling out during the quarter.
Y-Intercept (HK) sold 8,455 Kalaris Therapeutics shares in Q3 2024, an estimated $141K.
Y-Intercept (HK) first reported a position in Kalaris Therapeutics in Q2 2024 and held it in 1 quarter.
Y-Intercept (HK)'s Kalaris Therapeutics position peaked at $141K in Q2 2024.
59 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q3 2024.

Based on Y-Intercept (HK)'s 13F filing for Q3 2024, filed 15 Nov 2024.